Parkinson’s disease (PD) is a neurodegenerative disorder that affects multiple body systems and results in a variety of motor and non-motor symptoms. Recent research has highlighted the importance of secretome, a diverse array of bioactive molecules produced by mesenchymal stem cells (MSCs). This study explores the progress and potential benefits of secretome use in treating PD. A scoping review was conducted following the Preferred Reporting Items for Scoping Reviews protocol, utilizing journals from PubMed Central, ScienceDirect, and Scopus databases with no time restrictions. The findings suggest that secretome shows promise in developing new therapies for PD, particularly due to its superior antioxidant, neuroprotective, and neurodifferentiation effects on dopaminergic neurons compared to MSCs. These effects have been linked to notable improvements in motor, behavioral, and morphological changes. However, for secretome therapy to be effectively implemented in human patients with PD, factors such as production stages, release mechanisms, and administration routes require further investigation.
Key words: Parkinson's disease, secretome, paracrine, neurology, progenitor cell, stem cell
|
